Diode Laser Photocoagulation With Immediate Implant Placement
Launched by HAMS HAMED ABDELRAHMAN · Jun 22, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to place dental implants right after removing a tooth in the upper front area of the mouth, which is important for a natural-looking smile. The study is looking at whether using a special laser treatment called diode laser photocoagulation, along with a customized healing part, can help improve healing of the bone and gum tissue around the implant. This approach aims to shorten treatment time, make the process more comfortable, and help the gums and bone stay healthy to prevent infections.
People who might be eligible for this trial are adults who need to have a severely damaged or infected upper front tooth removed and replaced immediately with an implant. To join, participants should have good oral hygiene and a specific type of tooth socket after extraction that allows for immediate implant placement. People with certain conditions like damaged bone, heavy smoking habits, or certain medical treatments affecting bone healing would not be eligible. Participants can expect to undergo the tooth removal and implant placement with the laser treatment to see if this method helps improve healing and long-term success of the implant.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with non-restorable maxillary teeth in the aesthetic zone are indicated for extraction and subsequent immediate implant placement, including those with:
- • A severely carious tooth that cannot be restored.
- • Pulpal necrosis or irreversible pulpitis that is not amenable to endodontics.
- • Periodontally involved teeth with grade 2 mobility or above.
- • Teeth with root caries that can't be restored.
- • Patients with an extraction socket Type I.
- • A good standard of oral hygiene.
- Exclusion Criteria:
- • Patients with extraction socket Type II or III, with buccal plate defects.
- • Absence of at least 2 mm of bone apical to the extraction socket
- • tooth ankylosis.
- • Patients with deciduous teeth.
- • Heavy smokers.
- • Systemic conditions
- • History of oral or intravenous bisphosphonate therapy or any treatments with other medications that may interfere with bone metabolism within the past 12 months
About Hams Hamed Abdelrahman
Hams Hamed Abdelrahman is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on ethical practices and regulatory compliance, the organization prioritizes patient safety and data integrity in all its clinical trials. Leveraging a diverse team of experienced professionals, Hams Hamed Abdelrahman collaborates with healthcare providers and research institutions to facilitate the development of new therapies and interventions that address unmet medical needs across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported